Summer Street Research Partners, an investment banking, institutional equity research and trading firm that focuses on the healthcare sector expands its research team by adding Ling Wang as its newest senior biotechnology analyst and director.
Wang, with years of equity research experience, will be focused on covering the biotechnology sector, continuing to build out the biotechnology sector for the firm.
“We are very excited to welcome Ling to the research team at Summer Street. Ling is a proven analyst with extensive Wall Street experience,” says Dr. Mark Landy, director of research for Summer Street Research. “We believe Ling will bring valuable insights and a unique perspective to our research product, which will benefit our clients.”
Before joining Summer Street, Wang was senior vice president and senior biotechnology analyst at Brean Murray, Carret & Co. Prior her stint at Brean Murray, she was a research associate covering biotechnology stocks at Rodman & Renshaw from 2006 to 2008.
Wang earned her undergraduate degree in biology from Beijing University and also holds a master’s degree in molecular pharmacology from Albert Einstein College of Medicine and an MBA degree in finance from Yale University.
“I’m very excited to join Summer Street,” says Wang. “With their unique MCRI consulting network and their singular focus on the healthcare sector, I believe Summer Street is the right platform for me to add real value to institutional healthcare investors on important and timely topics.”
Summer Street Research Partners was founded in 2002 and provides a proprietary equity research, uses more than 10,000 physicians and industry professionals provided through its MCRI division.
